Video
Journals
Specialty Area
Topics
Institute for Value-Based Medicine
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Advertisement
Contact Info
2 Commerce Drive
Cranbury, NJ 08512
© 2026 MJH Life Sciences
AJMC®
All rights reserved.
AJMC®
All rights reserved.
Social Determinants of Health
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Panelists discuss how social determinants such as access, income, and literacy drive disparities in LDL-C control.
EP: 1.Understanding the Current State of LDL-C Goal Attainment and Barriers to Adequate Control in Hyperlipidemia
EP: 2.Challenges with Undertreatment in Hyperlipidemia and Opportunities to Address this Gap
EP: 3.Pharmacy-Driven Challenges
EP: 4.Real-World Insights and PROMPT-LIPID
EP: 5.Social Determinants of Health
EP: 6.The 2013 Guideline Shift
EP: 7.Unintended Consequences of Metric Changes
EP: 8.Reinstating LDL-C Targets
EP: 9.International LDL Thresholds
EP: 10.Nonstatin Therapy Decisions
EP: 11.PCSK9 Inhibitor Underuse
EP: 12.Payer and Prior Authorization Barriers
EP: 13.Adherence and Persistence
EP: 14.Cumulative LDL-C Exposure
EP: 15.Economic Burden and Systemwide Strategies
Panelists discuss how social determinants of health profoundly shape cholesterol control and patient engagement. Income, access to transportation, education, and health care coverage all influence adherence to low-density lipoprotein (LDL)–lowering therapy.
They emphasize that patients facing economic hardship are less likely to fill prescriptions, attend follow-up visits, or afford nonstatin agents. Cultural and language barriers further complicate communication around risk and treatment.
Panelists advocate for patient-centered strategies that integrate social support, care navigation, and community-based screening programs to reduce disparities in LDL cholesterol management.
Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma
January 23rd 2026Phase 2 trial results show anlotinib with anthracyclines and ifosfamide yields a 30.8% ORR and an 82.7% DCR in advanced soft tissue sarcoma.
Read More
Switching From MA to TM Increases Mental Health Care Use: Angela Liu, PhD, MPH
December 23rd 2025Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.
Listen
Oral Nalbuphine Significantly Reduces Chronic Cough in IPF
January 22nd 2026Oral nalbuphine significantly reduced cough frequency and severity in idiopathic pulmonary fibrosis (IPF), with patients seeing greater benefit at higher doses.
Read More
Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care
November 25th 2025Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.
Listen
FDA Draft Guidance Proposes CR, MRD to Accelerate MM Drug Approval
January 21st 2026The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival indicators.
Read More
By Improving Sleep, TNX-102 SL Reduces Pain and Fatigue in Fibromyalgia
January 21st 2026Sleep-focused TNX-102 SL delivered significant benefits in a phase 3 fibromyalgia study.
Read More
Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma
January 23rd 2026Phase 2 trial results show anlotinib with anthracyclines and ifosfamide yields a 30.8% ORR and an 82.7% DCR in advanced soft tissue sarcoma.
Read More
Switching From MA to TM Increases Mental Health Care Use: Angela Liu, PhD, MPH
December 23rd 2025Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.
Listen
Oral Nalbuphine Significantly Reduces Chronic Cough in IPF
January 22nd 2026Oral nalbuphine significantly reduced cough frequency and severity in idiopathic pulmonary fibrosis (IPF), with patients seeing greater benefit at higher doses.
Read More
Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care
November 25th 2025Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.
Listen
FDA Draft Guidance Proposes CR, MRD to Accelerate MM Drug Approval
January 21st 2026The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival indicators.
Read More
By Improving Sleep, TNX-102 SL Reduces Pain and Fatigue in Fibromyalgia
January 21st 2026Sleep-focused TNX-102 SL delivered significant benefits in a phase 3 fibromyalgia study.
Read More